BeOne Medicines (ONC) Financials

BeOne Medicines (NASDAQ: ONC) showed a clear improvement in profitability and liquidity in Q1 2026 versus the same periods in 2025 and 2024, but the company still operates with a heavy expense base and meaningful debt. The latest quarter featured strong revenue growth, positive operating cash flow, and a larger cash position, while retained earnings remain deeply negative, reflecting years of accumulated losses.

• Revenue continued to grow: Q1 2026 revenue rose to $1.51 billion, up from $1.50 billion in Q4 2025 and $1.12 billion in Q1 2025, extending the company’s strong top-line trend over the last year.
• Gross profit remained very strong: Q1 2026 gross profit was $1.35 billion, supported by a relatively low cost of revenue of $167.2 million.
• Operating income improved sharply year over year: Q1 2026 operating income was $249.9 million, compared with $11.1 million in Q1 2025 and a loss of $261.3 million in Q1 2024.
• Net income was solidly positive: The company earned $227.4 million in Q1 2026, a strong improvement from $127.0 million in Q1 2025 and a loss of $251.2 million in Q1 2024.
• Operating cash flow stayed positive: Q1 2026 operating cash flow was $201.3 million, showing the business is still generating cash from operations despite heavy R&D spending.
• Cash balance increased meaningfully: Cash and equivalents rose to $4.79 billion at March 31, 2026, up from $4.04 billion at September 30, 2025 and $2.52 billion at March 31, 2025.
• Debt leverage looks manageable relative to cash: Total debt was about $1.08 billion in Q1 2026, while cash alone was more than 4 times that amount.
• Margins were still pressured by high operating expenses: Q1 2026 SG&A was $555.1 million and R&D was $541.2 million, keeping total operating expenses above $1.09 billion.
• Share count remains elevated: Diluted weighted average shares outstanding were 1.50 billion in Q1 2026, so earnings growth is being spread across a large share base.
• Balance sheet equity is improving but still reflects past losses: Retained earnings remained negative at -$8.09 billion, indicating a long history of cumulative losses despite recent profit improvement.
• Current liabilities are sizable: Total current liabilities were $1.81 billion in Q1 2026, led by $1.08 billion in accrued expenses and $423.5 million in accounts payable.
• Investing and financing activity still supports the business: The company continues to spend on capital expenditures and occasionally uses debt issuance, suggesting the business still requires substantial funding flexibility.

Looking at the trend over the past four years, BeOne Medicines has moved from deep losses in 2023 and early 2024 toward much stronger profitability by late 2025 and early 2026. Revenue has steadily expanded, operating cash flow has turned consistently positive, and the balance sheet has strengthened with a larger cash cushion. The main watch item for investors is whether the company can keep scaling revenue faster than operating costs, especially R&D and SG&A, which remain very high.

Bottom line: ONC appears to be in a much healthier financial position than it was a year ago, with improving earnings, strong cash generation, and a large liquidity buffer. That said, investors should still expect elevated spending and some volatility as the company continues to invest for growth.